Affimed in the spotlight

AFM13 data announcement at ASH conference

Affimed (AFMD) gave an update at the ASH conference this weekend for their AFM13 program in both monotherapy and combination with NK. The monotherapy data was a disappointment, while the NK combination continued to provide promising updates.

AFM13 Monotherapy Data
This was a Phase-2 study using AFM13 as a monotherapy in patients with relapsed/refractory p…